Study #2024-1202
A randomized phase II, double-blind, multicenter study evaluating the efficacy and safety of autogene Cevumeran plus Nivolumab versus Nivolumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Autogene Cevumeran, Nivolumab, Saline
Description
The main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in participants with high risk MIUC. In this study participants will be enrolled in a safety run-in phase to receive autogene cevumeran + nivolumab. This phase will be conducted to monitor and ensure the safety of study participants. After all participants in the safety run-in have been enrolled to receive autogene cevumeran + nivolumab, further participants will be randomization in either autogene cevumeran + nivolumab or the saline + nivolumab arm.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Muscle Invasive Urothelial Carcinoma
Study phase:
Phase II
Physician name:
Omar Alhalabi
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-211-1427
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.